Linezolid for Treatment of Vancomycin-Resistant Enterococcal Peritonitis

American Journal of Kidney Diseases

Volumn 38, Issue 4 SUPPL. 3, 2001, Pages e20.1-e20.3

  Bailey, Elaine M ^a   Faber, Mark D ^b   Nafziger, Daniel A ^b  

^a Ortho McNeil Pharmaceuticals   (United States)

^b NONE

Author keywords

CAPD associated peritonitis; Continuous ambulatory peritoneal dialysis (CAPD); Linezolid; Peritoneal dialysis; Peritonitis; Vancomycin resistant Enterococcus

Indexed keywords

EID: 0347081597     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.27729     Document Type: Article

References (13)

1. Zelenitsky S, Barns L, Findlay I, Alfa M, Ariano R, Fine A, Harding G: Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. Am J Kidney Dis 36:1009-1013, 2000
2. Piraino B: Peritonitis as a complication of peritoneal dialysis. J Am Soc Nephrol 9:1956-1964, 1998
3. Beltrami EM, Singer DA, Fish L, Manning K, Young S, Banerjee SN, Baker R, Jarvis WR: Risk factors for acquisition of vancomycin-resistant enterococci among patients on a renal ward during a community hospital outbreak. Am J Infect Control 28:282-285, 2000
4. Fridkin SK: Vancomycin-intermediate and -resistant Staphylococcus aureus: What the infectious disease specialist needs to know. Clin Infect Dis 32:108-115, 2001
5. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR: Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 340:493-501, 1999
6. Golper TA, Schulman G, D'Agata EM: Indications for vancomycin in dialysis patients. Semin Dial 13:389-392, 2000
7. Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, Kawaguchi Y, Piraino B, Riella M, Vas S: Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int 20:396-411, 2000
8. Moses J, Brown E, Lynn W, White J, Goldberg LK, Talbot GH: Treatment of vancomycin-resistant Enterococcus faecium CAPD-associated peritonitis with intraperitoneal administration of quinupristin/dalfopristin. Abstracts of the 38th ICAAC, San Diego, CA, September 24-27, 1998
9. Troidle L, Kliger AS, Gorban-Brennan N, Fikrig M, Golden M, Finkelstein FO: Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococci. Kidney Int 50:1368-1372, 1996
10. Lynn W, Wont S, Lacey S, Rogers TR, Cohen J: Treatment of peritoneal dialysis-associated peritonitis due to vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin/dalfopristin). Abstracts of the 34th ICAAC, Orlando, FL, 1994
11. Bowker KE, Wooton M, Holt HA, Macgowan AP: In vitro activity of linezolid against gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis (CAPD) patients. Abstracts of the 40th ICAAC, Toronto, Ontario, 2000
12. Rybak MJ, Hershberger E, Moldovan T, Grucz RG: In-vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and resistant strains. Antimicrob Agents Chemother 44:1062-1066, 2000
13. Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR: In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 43:2059-2062, 1999